Published in Purinergic Signal on June 09, 2015
Interactions of Pannexin1 channels with purinergic and NMDA receptor channels. Biochim Biophys Acta (2017) 0.75
Jiang Tang Xiao Ke Granule, a Classic Chinese Herbal Formula, Improves the Effect of Metformin on Lipid and Glucose Metabolism in Diabetic Mice. Evid Based Complement Alternat Med (2016) 0.75
The Immune Landscape in Nonalcoholic Steatohepatitis. Immune Netw (2016) 0.75
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 4.98
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature (2010) 4.10
Purinergic signaling during inflammation. N Engl J Med (2012) 4.08
Pannexin 1 in erythrocytes: function without a gap. Proc Natl Acad Sci U S A (2006) 4.03
Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab (2006) 3.71
Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57
Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology (2009) 3.20
Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci (2007) 3.01
Ischemia opens neuronal gap junction hemichannels. Science (2006) 3.00
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol (2006) 2.96
The pannexin 1 channel activates the inflammasome in neurons and astrocytes. J Biol Chem (2009) 2.90
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
ATP4- permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. J Biol Chem (1987) 2.69
Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. J Immunol (2011) 2.67
P2X7 receptor-Pannexin1 complex: pharmacology and signaling. Am J Physiol Cell Physiol (2008) 2.49
Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity (2011) 2.47
Activation of pannexin-1 hemichannels augments aberrant bursting in the hippocampus. Science (2008) 2.46
CCR2 promotes hepatic fibrosis in mice. Hepatology (2009) 2.35
A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology (2012) 2.15
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut (2011) 2.06
Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One (2010) 1.94
Pannexin 1 contributes to ATP release in airway epithelia. Am J Respir Cell Mol Biol (2009) 1.89
Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol (2012) 1.87
C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes (2010) 1.86
Rho signaling regulates pannexin 1-mediated ATP release from airway epithelia. J Biol Chem (2011) 1.76
The biochemistry and function of pannexin channels. Biochim Biophys Acta (2012) 1.70
Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci (2001) 1.65
An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology (2011) 1.60
Roles for chemokines in liver disease. Gastroenterology (2014) 1.59
Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol (2009) 1.48
Essential role for Ca2+ in regulation of IL-1beta secretion by P2X7 nucleotide receptor in monocytes, macrophages, and HEK-293 cells. Am J Physiol Cell Physiol (2003) 1.45
Pannexin 1, an ATP release channel, is activated by caspase cleavage of its pore-associated C-terminal autoinhibitory region. J Biol Chem (2012) 1.44
Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr (2002) 1.41
Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology (2008) 1.39
P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J (2008) 1.38
Role of toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. Gastroenterol Res Pract (2011) 1.37
Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.32
The P2X(7) receptor-pannexin connection to dye uptake and IL-1beta release. Purinergic Signal (2009) 1.32
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol (2011) 1.22
Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol (2011) 1.21
Characterization of ionotrophic purinergic receptors in hepatocytes. Hepatology (2008) 1.13
Rho-family GTPases modulate Ca(2+) -dependent ATP release from astrocytes. Am J Physiol Cell Physiol (2008) 1.13
Concomitant activation of P2Y(2) and P2Y(6) receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion. Eur J Immunol (2009) 1.11
P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. Am J Physiol Gastrointest Liver Physiol (2012) 1.10
JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab (2010) 1.10
NTPDase1 governs P2X7-dependent functions in murine macrophages. Eur J Immunol (2010) 1.09
Differentiating connexin hemichannels and pannexin channels in cellular ATP release. FEBS Lett (2014) 1.01
P2X7 receptor activates multiple selective dye-permeation pathways in RAW 264.7 and human embryonic kidney 293 cells. Mol Pharmacol (2009) 1.00
Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis. J Virol (2014) 0.94
The role of nucleotides in apoptotic cell clearance: implications for disease pathogenesis. J Mol Med (Berl) (2010) 0.91
Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators Inflamm (2006) 0.88
Pannexin1 contributes to pathophysiological ATP release in lipoapoptosis induced by saturated free fatty acids in liver cells. Am J Physiol Cell Physiol (2012) 0.83
Connexin and pannexin (hemi)channels in the liver. Front Physiol (2014) 0.83
Pathological roles of purinergic signaling in the liver. J Hepatol (2012) 0.82
Evidence for sustained ATP release from liver cells that is not mediated by vesicular exocytosis. Purinergic Signal (2011) 0.79
Nucleotides regulate secretion of the inflammatory chemokine CCL2 from human macrophages and monocytes. Mediators Inflamm (2014) 0.77
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Cholangiocarcinoma. Gastroenterology (2005) 3.15
Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02
Lysosomes in cell death. Oncogene (2004) 3.00
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity (2008) 2.48
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45
Life and death by death receptors. FASEB J (2009) 2.39
Cholangiocarcinoma. Clin Liver Dis (2008) 2.33
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99
Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88
Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol (2004) 1.66
Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol (2006) 1.66
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl (2007) 1.64
Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63
Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci (2005) 1.63
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology (2006) 1.60
The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther (2003) 1.60
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Liver transplantation for cholangiocarcinoma. Transpl Int (2010) 1.58
Cholangiocytes exhibit dynamic, actin-dependent apical membrane turnover. Am J Physiol Cell Physiol (2002) 1.56
Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol (2010) 1.56
Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ Res (2002) 1.56
Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology (2009) 1.55
Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55
CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.54
Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) (2011) 1.54
Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53
Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology (2010) 1.53
miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology (2011) 1.52
IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52
"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol (2012) 1.51
Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol (2003) 1.50
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology (2009) 1.49
Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol (2003) 1.48
Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol (2002) 1.47
The emergence of a new discipline, hepatobiliary oncology. Hepatology (2008) 1.46
TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology (2008) 1.45
Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem (2007) 1.43
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.43
Comparison of methods to detect neoplasia in patients undergoing endoscopic ultrasound-guided fine-needle aspiration. Gastroenterology (2012) 1.43
Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation (2006) 1.43
Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol (2013) 1.43
Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology (2006) 1.42
Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology (2008) 1.41
Primary sclerosing cholangitis: summary of a workshop. Hepatology (2006) 1.38
Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res (2002) 1.37
Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology (2005) 1.37
Death receptor-mediated apoptosis and the liver. J Hepatol (2002) 1.37
Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem (2002) 1.36